Pfizer to receive $29 million from SEC case involving Steven A. Cohen’s hedge fund

Pfizer is close to settling a legal dispute related to insider trading, marking the end of a long appeal process. The funds left over from SAC Capital’s settlement with the SEC could be used to resolve the matter. However, court approval is still needed before the settlement can be finalized.

The resolution of this case would bring an end to Pfizer’s appeal, which has been ongoing for some time. The company has been involved in a legal battle over allegations of insider trading, and a settlement could finally put the matter to rest. The money that remains from SAC Capital’s settlement with the SEC could play a crucial role in resolving this issue.

While the settlement is nearing completion, it is important to note that court approval is necessary before it can be officially accepted. This step is crucial in ensuring that all parties involved are in agreement with the terms of the settlement. Once the court gives its approval, the settlement will be finalized, and Pfizer’s appeal will come to an end.

Overall, the potential settlement between Pfizer and the SEC regarding insider trading allegations could bring closure to a long-standing legal dispute. The funds left over from SAC Capital’s settlement may be used to reach an agreement in the case. However, court approval is still required before the settlement can be officially accepted. This development could mark the end of Pfizer’s appeal and provide resolution to the insider trading allegations that have been looming over the company.